{"disease":{"id":"anti-pd1-antibody","name":"anti pd1 antibody"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04627012","title":"Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06323382","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06550921","title":"Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06740370","title":"TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07038915","title":"STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}